Close

Pfizer's (PFE) Palbociclib Has $5 Billion Potential

April 10, 2013 11:17 AM EDT Send to a Friend
This morning Pfizer Inc. (NYSE: PFE) announced its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login